Relationship between erb-B2 mRNA Expression in Blood and Tissue of Invasive Ductal Carcinoma Breast Cancer Patients and Clinicopathological Characteristics of the Tumors

Moazzezy, Neda; Ebrahimi, Fatemeh; Sisakht, Mahsa Mollapour; Yahyazadeh, Hossein; Bouzari, Saeid; Oloomi, Mana

doi:10.7314/apjcp.2016.17.1.249

Cited by 3 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results suggest that the detection of circulating HER-2 mRNA may be a useful predictive method for breast cancer diagnosis, complementary to tissue analysis. However, a previous study identified no correlation between blood HER-2 mRNA level and tissue HER-2 status ( 48 ). Additionally, no associations were observed between the blood HER-2 mRNA level, and the lymph node status, tumor grade, tumor stage, tumor size, patient age, menopausal status, or ER or PR status of the primary tumor in a previous study ( 49 ).…”

Section: Discussionmentioning

confidence: 94%

Circulating HER‑2 mRNA in the peripheral blood as a potential diagnostic and prognostic biomarker in females with breast cancer

Meng²,

Yang

et al. 2018

Oncol Lett

View full text Add to dashboard Cite

Breast cancer is a prevalent malignant cancer worldwide, and a lack of defined biomarkers for early prognostication contributes to its high associated mortality rate, especially in human epidermal growth factor receptor 2 (HER-2)-positive breast cancer. In the present study, HER-2 mRNA levels in patients were detected prior to surgery and during neoadjuvant chemotherapy to explore its potential diagnostic and prognostic value. Blood samples were collected from 70 patients with breast cancer, including 50 HER-2-negative and 20 HER-2-positive patients, prior to and following surgery (postoperative, n=13; neoadjuvant chemotherapy, n=5); the control group included 35 samples from healthy individuals. The relative mRNA level of HER-2 in blood was determined by one-step reverse transcription-quantitative polymerase chain reaction. HER-2 expression curves of measurements taken during neoadjuvant chemotherapy were compared with the tumor size. A significant difference in the blood HER-2 mRNA level was observed between healthy women and patients with breast cancer (P<0.0001). A cutoff value of 1.512 was established for the circulating HER-2 level in healthy subjects based on the upper 95% confidence interval value of samples from the control group. The level of HER-2 mRNA in blood was associated with the HER-2 status, Ki-67 expression, and lymphovascular invasion in primary tumor tissue samples; however, there was no association with the lymph node status, tumor stage, tumor grade, tumor size, patient age, estrogen or progesterone receptor status of the primary tumor. HER-2 mRNA levels were associated with the response rate, as determined by primary tumor size, in patients who received neoadjuvant chemotherapy. In conclusion, baseline and early changes in peripheral blood HER-2 mRNA indicated that HER-2 mRNA may be a potential diagnostic biomarker for breast cancer and a prognostic marker for predicting the efficacy of neoadjuvant therapy.

show abstract

Section: Discussionmentioning

confidence: 94%

Circulating HER‑2 mRNA in the peripheral blood as a potential diagnostic and prognostic biomarker in females with breast cancer

Meng²,

Yang

et al. 2018

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…The study of the presence and expression of the various tumor-associated circulating transcripts (TACTs) in the peripheral blood of BC patients through transcriptomics-based analyses may help to discriminate between controls and patients, to profile BC subtypes, or to decipher the mechanisms involved in BC development and progression. Thus, many potential biomarkers for the diagnosis and evaluation of BC progression have been identified in peripheral blood by assessing the expressions of human mammoglobin A (MAM) mRNA [ 187 ], ERBB2/HER2 mRNA [ 188 , 189 ], EPCAM, KRT19, MKI67, TERT, VIM, NPTN, MCAM, SNAI2, and FOXA2 mRNAs [ 190 ]. mRNA-based diagnostic blood tests have been developed for the early detection of BC, which are cost-effective and high-throughput [ 185 , 190 , 191 ].…”

Section: Breast Cancer Investigation In the Multi-omics Eramentioning

confidence: 99%

Omics-Based Investigations of Breast Cancer

Neagu,

Whitham,

Bruno

et al. 2023

Molecules

View full text Add to dashboard Cite

Breast cancer (BC) is characterized by an extensive genotypic and phenotypic heterogeneity. In-depth investigations into the molecular bases of BC phenotypes, carcinogenesis, progression, and metastasis are necessary for accurate diagnoses, prognoses, and therapy assessments in predictive, precision, and personalized oncology. This review discusses both classic as well as several novel omics fields that are involved or should be used in modern BC investigations, which may be integrated as a holistic term, onco-breastomics. Rapid and recent advances in molecular profiling strategies and analytical techniques based on high-throughput sequencing and mass spectrometry (MS) development have generated large-scale multi-omics datasets, mainly emerging from the three ”big omics”, based on the central dogma of molecular biology: genomics, transcriptomics, and proteomics. Metabolomics-based approaches also reflect the dynamic response of BC cells to genetic modifications. Interactomics promotes a holistic view in BC research by constructing and characterizing protein–protein interaction (PPI) networks that provide a novel hypothesis for the pathophysiological processes involved in BC progression and subtyping. The emergence of new omics- and epiomics-based multidimensional approaches provide opportunities to gain insights into BC heterogeneity and its underlying mechanisms. The three main epiomics fields (epigenomics, epitranscriptomics, and epiproteomics) are focused on the epigenetic DNA changes, RNAs modifications, and posttranslational modifications (PTMs) affecting protein functions for an in-depth understanding of cancer cell proliferation, migration, and invasion. Novel omics fields, such as epichaperomics or epimetabolomics, could investigate the modifications in the interactome induced by stressors and provide PPI changes, as well as in metabolites, as drivers of BC-causing phenotypes. Over the last years, several proteomics-derived omics, such as matrisomics, exosomics, secretomics, kinomics, phosphoproteomics, or immunomics, provided valuable data for a deep understanding of dysregulated pathways in BC cells and their tumor microenvironment (TME) or tumor immune microenvironment (TIMW). Most of these omics datasets are still assessed individually using distinct approches and do not generate the desired and expected global-integrative knowledge with applications in clinical diagnostics. However, several hyphenated omics approaches, such as proteo-genomics, proteo-transcriptomics, and phosphoproteomics-exosomics are useful for the identification of putative BC biomarkers and therapeutic targets. To develop non-invasive diagnostic tests and to discover new biomarkers for BC, classic and novel omics-based strategies allow for significant advances in blood/plasma-based omics. Salivaomics, urinomics, and milkomics appear as integrative omics that may develop a high potential for early and non-invasive diagnoses in BC. Thus, the analysis of the tumor circulome is considered a novel frontier in liquid biopsy. Omics-based investigations have applications in BC modeling, as well as accurate BC classification and subtype characterization. The future in omics-based investigations of BC may be also focused on multi-omics single-cell analyses.

show abstract

“…It is over-expressed in about 20% of invasive breast cancers. Particularly, it has been shown that ERBB2 over-expression boosts invasion and metastasis of breast cancer and is correlated with poor survival of patients ( 118 ). Identification of the deregulated ERBB2 pathway in breast cancer pathogenesis has led to the development of ERBB2 targeted therapies.…”

Section: Most Common Cancers Treated With Gene Therapy: the Potentialmentioning

confidence: 99%

Strategies for Targeting Gene Therapy in Cancer Cells With Tumor-Specific Promoters

et al. 2020

View full text Add to dashboard Cite

Cancer is the second cause of death worldwide, surpassed only by cardiovascular diseases, due to the lack of early diagnosis, and high relapse rate after conventional therapies. Chemotherapy inhibits the rapid growth of cancer cells, but it also affects normal cells with fast proliferation rate. Therefore, it is imperative to develop other safe and more effective treatment strategies, such as gene therapy, in order to significantly improve the survival rate and life expectancy of patients with cancer. The aim of gene therapy is to transfect a therapeutic gene into the host cells to express itself and cause a beneficial biological effect. However, the efficacy of the proposed strategies has been insufficient for delivering the full potential of gene therapy in the clinic. The type of delivery vehicle (viral or non viral) chosen depends on the desired specificity of the gene therapy. The first gene therapy trials were performed with therapeutic genes driven by viral promoters such as the CMV promoter, which induces non-specific toxicity in normal cells and tissues, in addition to cancer cells. The use of tumor-specific promoters over-expressed in the tumor, induces specific expression of therapeutic genes in a given tumor, increasing their localized activity. Several cancer- and/or tumor-specific promoters systems have been developed to target cancer cells. This review aims to provide up-to-date information concerning targeting gene therapy with cancer- and/or tumor-specific promoters including cancer suppressor genes, suicide genes, anti-tumor angiogenesis, gene silencing, and gene-editing technology, as well as the type of delivery vehicle employed. Gene therapy can be used to complement traditional therapies to provide more effective treatments.

show abstract

Relationship between erb-B2 mRNA Expression in Blood and Tissue of Invasive Ductal Carcinoma Breast Cancer Patients and Clinicopathological Characteristics of the Tumors

Cited by 3 publications

References 20 publications

Circulating HER‑2 mRNA in the peripheral blood as a potential diagnostic and prognostic biomarker in females with breast cancer

Circulating HER‑2 mRNA in the peripheral blood as a potential diagnostic and prognostic biomarker in females with breast cancer

Omics-Based Investigations of Breast Cancer

Strategies for Targeting Gene Therapy in Cancer Cells With Tumor-Specific Promoters

Contact Info

Product

Resources

About